Regression of cardiac valvulopathy related to ergot-derived dopamine agonists

Cardiovascular Therapeutics

Volumn 29, Issue 6, 2011, Pages 404-410

  Zanettini, Renzo ^a   Antonini, Angelo ^a   Gatto, Gemma ^a   Gentile, Rosa ^a   Tesei, Silvana ^a   Pezzoli, Gianni ^a  

^a PARKINSON INSTITUTE   (Italy)

Author keywords

Cardiac valvulopathy regression; Drug discontinuation; Ergot derived dopamine agonists; Parkinson disease

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; PERGOLIDE;

AGED; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART VALVE REGURGITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

ADULT; AGED; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; ERGOLINES; FEMALE; FOLLOW-UP STUDIES; HEART VALVE DISEASES; HUMANS; ITALY; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT SELECTION; PERGOLIDE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 79955672955     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00169.x     Document Type: Article

References (20)

1. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinsons's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
2. Schade R, Andersohn F, Suissa F, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38.
3. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular Heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
4. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study. Neurology 2006;67:1225-1229.
5. Watanabe H, Hirayama M, Noda A, et al. B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist. Neurology 2009;72:621-626.
6. Bothero M, Fuchs R, Paulus DA. Carcinoid heart disease: A case report and literature review. J Clin Anesth 2002;14:57-63.
7. Bernheim AM, Connolly HM, Hobday TJ, Abel MD, Pellikka PA. Carcinoid heart disease. Prog Cardiovasc Dis 2007;49:439-451.
8. Wilke A, Hesse H, Hufnagel G, Maisch B. Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 1997;18:701.
9. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: A meta-analysis of observational studies. Am Heart J 2002;144:1065-1073.
10. Shively BK, Roldan CA, Gill EA, Najarian T, Barton Loar S. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100:2161-2167.
11. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings. Effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101:2071-2077.
12. Rajamannan NM, Caplice N, Anthikad F, et al. Cell proliferation in carcinoid valve disease: A mechanism for serotonin effects. J Heart Valve Dis 2001;10:827-831.
13. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-2841.
14. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
15. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829.
16. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261-266.
17. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802.
18. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a ranch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
19. Simonis G, Fuhrmann J, Strasser R. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov Disord 2007;22:1936-1942.
20. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-52.